Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Daniel Rayson, Sasha Lupichuk, Kylea Potvin, Susan Dent, Tamara Shenkier, Sukhbinder Dhesy-Thind, Susan L. Ellard, Catherine Prady, Muhammad Salim, Patricia Farmer, Ghasson Allo, Ming Sound Tsao, Alison Allan, Olga Ludkovski, Maria Bonomi, Dongsheng Tu, Linda Hagerman, Rachel Goodwin, Elizabeth Eisenhauer, Penelope Bradbury

科研成果: 期刊稿件文章同行评审

40 引用 (Scopus)

指纹

探究 'Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer' 的科研主题。它们共同构成独一无二的指纹。

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science